Efficacy and resistance of different artemisinin-based combination therapies: a systematic review and network meta-analysis

Abstract

Background: Malaria parasites have developed resistance to most of the known antimalarial drugs in clinical practice, with reports of artemisinin resistance emerging in South East Asia (SEA). We sort to find the status of artemisinin resistance and efficacy of different modalities of the current artemisinin-based combination therapies (ACTs). Methods: We carried out a systematic search in 11 electronic databases to identify in vivo studies published between 2001 and 2017 that reported artemisinin resistance. This was then followed by A network meta-analysis to compare the efficacy of different ACTs. Quality assessment was performed using the Cochrane Risk of Bias (ROB) tool for randomized controlled trials and National Institute of Health (NIH) tool for cross-sectional studies. The study protocol was registered in PROSPERO under number CRD42018087574. Results: With 8400 studies initially identified, 82 were eligible for qualitative and quantitative analysis. Artemisinin resistance was only reported in South East Asia. K13 mutation C580Y was the most abundant mutation associated with resistance having an abundance of 63.1% among all K13 mutations reported. Although the overall network meta-analysis had shown good performance of dihydroartemisinin piperaquine in the early years, a subgroup analysis of the recent years revealed a poor performance of the drug in relation to

Drinking water and sanitation conditions are associated with the risk of malaria among children under five years old in sub-Saharan Africa: A logistic regression model analysis of national survey data

“…Although cases of malaria have decreased by an estimated 20 million since 2010 [1], there was no significant progress in reducing the number of global cases from 2015 to 2017 [1]. Current efforts to prevent malaria mainly include preventive and symptomatic treatment with antimalarial compounds, consisting of artemisinin-based combination therapies [2], as well as vector control with long-lasting insecticidal mosquito nets (LLINs) and indoor residual spraying (IRS) [3], [4]; these methods have resulted in reductions in case incidence and mortality. However, increasing evidence has revealed that these efforts can only go so far [1], [5].…”

Antimalarial activity of basic phospholipases A2 isolated from Paraguayan Bothrops diporus venom against Plasmodium falciparum

“…Initially, cases of Chloroquine resistance were recorded in Southwest Asia and then in South America ( Nevin and Croft, 2016 ; Wongsrichanalai et al, 2002 ). Due this fact, since 2001, combined therapy with artemisinin (ATC) has been used in the treatment of malaria ( Su and Miller, 2015 ); however, failed treatments with ATC have been reported in strains of P. falciparum on the Thailand-Cambodia and Myanmar border, reaffirming the need for studies of new molecules with antiplasmodial potential ( Ashley et al, 2014 ; Bhumiratana et al, 2013 ; Mathenge et al, 2020 ).…”

A single oral fixed - dose praziquantel-miltefosine nanocombination for effective control of experimental Schistosomiasis mansoni

“…Such limitations led to the emergence of an innovative combination therapy approach based on multi-drug delivery nanocarriers with increasing benefits in diverse diseases, notably cancer (34,35). Although still in an early stage in the treatment of infectious diseases (36), the carrier-mediated multiple drug approach proved promising in the treatment of malaria (37,38).…”